Transgene's Liquidity Contract Update with Natixis Oddo BHF

Author: Dylan Bailey Updated: 07-08-2025 12:04 PM

Overview of Transgene’s Liquidity Contract

Transgene has entrusted its liquidity management to Natixis Oddo BHF SCA, ensuring effective handling of its financial resources. As of June 30, 2025, key highlights from this arrangement reveal significant activity in both shares and capital.

Resources Managed through the Liquidity Account

Currently, the liquidity account under management is notable for holding:

327,750 shares
€112,376

These resources play a crucial role in supporting Transgene's strategic operations and market activities.

Half-Year Performance in 2025

In the first half of 2025, the liquidity management saw considerable trading activity with a total of:

Purchases: 249,004 shares valued at €180,297 across 769 market transactions.
Sales: 280,915 shares for €212,020 accomplished in 967 market transactions.

This trading volume demonstrates the effectiveness of the liquidity strategy implemented by Natixis Oddo BHF SCA.

Comparative Analysis of Managed Resources

To understand the progression within the liquidity account, it's important to compare current figures with past data:

End of 2024: 359,661 shares and €80,653.30 were managed.
Transfer to Natixis Oddo BHF SCA (January 2, 2020): Resources included 164,183 shares and €246,158.
Initial Setup in 2016: The liquidity program commenced with €500,000 in resources.

This historical perspective indicates that there have been fluctuations in both share numbers and capital as Transgene navigates through market conditions.

Importance of Effective Liquidity Management

Effective liquidity management is vital for any company, particularly for Transgene. By engaging Natixis Oddo BHF SCA, Transgene demonstrates its commitment to maintaining healthy market activity and ensuring that it has the necessary resources available for operational flexibility.

The management of shares and liquidity not only reflects on the current financial health but also supports strategic objectives and growth ambitions.

Future Prospects

As the market continues to evolve, Transgene’s strategic partnership with Natixis Oddo BHF SCA will likely adapt to these changes, ensuring calculated responses to market dynamics. Stakeholders can expect ongoing adjustments in the liquidity strategy as they work to optimize resources effectively.

Contact Information for Inquiries

For further information regarding the liquidity management and any associated inquiries, please reach out to:

Transgene
Lucie Larguier
Chief Financial Officer
+33 (0)3 88 27 91 00
investorrelations@transgene.fr

Frequently Asked Questions

What is the purpose of the liquidity contract with Natixis Oddo BHF?

The liquidity contract facilitates efficient management of Transgene’s shares and financial resources to enhance market activity.

How many shares were managed as of June 30, 2025?

As of that date, 327,750 shares were managed through the liquidity account.

What were the total purchases in the first half of 2025?

Total purchases amounted to 249,004 shares, valued at €180,297.

What comparisons can be made with previous years?

Comparative analysis shows variations in the management resources, with 359,661 shares and €80,653.30 managed at the end of 2024.

Who is the contact person for investor relations at Transgene?

Lucie Larguier, the Chief Financial Officer, is the point of contact for investor relations.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.